These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27742500)

  • 1. Sclerostin deficiency in humans.
    van Lierop AH; Appelman-Dijkstra NM; Papapoulos SE
    Bone; 2017 Mar; 96():51-62. PubMed ID: 27742500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.
    Sebastian A; Loots GG
    Metabolism; 2018 Mar; 80():38-47. PubMed ID: 29080811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover.
    van Lierop AH; Hamdy NA; Hamersma H; van Bezooijen RL; Power J; Loveridge N; Papapoulos SE
    J Bone Miner Res; 2011 Dec; 26(12):2804-11. PubMed ID: 21786318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers.
    van Lierop AH; Hamdy NA; van Egmond ME; Bakker E; Dikkers FG; Papapoulos SE
    J Bone Miner Res; 2013 Apr; 28(4):848-54. PubMed ID: 23074140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sclerostin: current knowledge and future perspectives.
    Moester MJ; Papapoulos SE; Löwik CW; van Bezooijen RL
    Calcif Tissue Int; 2010 Aug; 87(2):99-107. PubMed ID: 20473488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Dickkopf 1 levels in sclerostin deficiency.
    van Lierop AH; Moester MJ; Hamdy NA; Papapoulos SE
    J Clin Endocrinol Metab; 2014 Feb; 99(2):E252-6. PubMed ID: 24302746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin deficiency is linked to altered bone composition.
    Hassler N; Roschger A; Gamsjaeger S; Kramer I; Lueger S; van Lierop A; Roschger P; Klaushofer K; Paschalis EP; Kneissel M; Papapoulos S
    J Bone Miner Res; 2014 Oct; 29(10):2144-51. PubMed ID: 24753092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sclerosteosis: Report of type 1 or 2 in three Indian Tamil families and literature review.
    Whyte MP; Deepak Amalnath S; McAlister WH; Pedapati R; Muthupillai V; Duan S; Huskey M; Bijanki VN; Mumm S
    Bone; 2018 Nov; 116():321-332. PubMed ID: 30077757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
    Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerostin and skeletal health.
    Sharifi M; Ereifej L; Lewiecki EM
    Rev Endocr Metab Disord; 2015 Jun; 16(2):149-56. PubMed ID: 25669441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting sclerostin as potential treatment of osteoporosis.
    Papapoulos SE
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i119-22. PubMed ID: 21339215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerostin: recent advances and clinical implications.
    Honasoge M; Rao AD; Rao SD
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):437-46. PubMed ID: 25333305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-sclerostin - is there an indication?
    Larsson S
    Injury; 2016 Jan; 47 Suppl 1():S31-5. PubMed ID: 26768288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).
    Balemans W; Ebeling M; Patel N; Van Hul E; Olson P; Dioszegi M; Lacza C; Wuyts W; Van Den Ende J; Willems P; Paes-Alves AF; Hill S; Bueno M; Ramos FJ; Tacconi P; Dikkers FG; Stratakis C; Lindpaintner K; Vickery B; Foernzler D; Van Hul W
    Hum Mol Genet; 2001 Mar; 10(5):537-43. PubMed ID: 11181578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene.
    Balemans W; Cleiren E; Siebers U; Horst J; Van Hul W
    Bone; 2005 Jun; 36(6):943-7. PubMed ID: 15869924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.
    van Bezooijen RL; ten Dijke P; Papapoulos SE; Löwik CW
    Cytokine Growth Factor Rev; 2005 Jun; 16(3):319-27. PubMed ID: 15869900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis.
    Yavropoulou MP; Xygonakis C; Lolou M; Karadimou F; Yovos JG
    Hormones (Athens); 2014; 13(4):323-37. PubMed ID: 25555179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel SOST gene mutation in a sclerosteosis patient from Morocco: a case report.
    Belkhribchia MR; Collet C; Laplanche JL; Hassani R
    Eur J Med Genet; 2014 Mar; 57(4):133-7. PubMed ID: 24594238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.
    van Bezooijen RL; Papapoulos SE; Löwik CW
    J Endocrinol Invest; 2005; 28(8 Suppl):15-7. PubMed ID: 16323824
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.